NovoCureBSP:N2VC34 46 Return-on-Tangible-Equity is -82.97% as of Mar. 2026. GuruFocus rates BSP:N2VC34 with a GF Score™ of 46/100 and a GF Value™ of R$8.98 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 760 Medical Devices & Instruments companies, NovoCure ranks worse than 81.05% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. NovoCure's annualized net income for the quarter that ended in Mar. 2026 was R$-1,488 Mil. NovoCure's average shareholder tangible equity for the quarter that ended in Mar. 2026 was R$1,793 Mil. Therefore, NovoCure's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -82.97%.
The historical rank and industry rank for NovoCure's Return-on-Tangible-Equity or its related term are showing as below:
BSP:N2VC34'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -67.07 Med: -42.78 Max: 5.71
Current: -50.19
During the past 13 years, NovoCure's highest Return-on-Tangible-Equity was 5.71%. The lowest was -67.07%. And the median was -42.78%.
BSP:N2VC34's Return-on-Tangible-Equity is ranked worse than 81.05% of 760
companies
in the Medical Devices & Instruments industry
Industry Median: 4.115
vs BSP:N2VC34: -50.19
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
NovoCure Return-on-Tangible-Equity Related Terms
NovoCure Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for NovoCure's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:N2VC34 vs NEOG, ESTA, AXGN: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, NovoCure's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovoCure Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where NovoCure's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -82.97% mean?
NovoCure (BSP:N2VC34) has a Return-on-Tangible-Equity of -82.97% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on NovoCure and its competitors. According to the industry distribution chart, NovoCure ranks #616 out of 760 companies in the Medical Devices & Instruments industry, placing it in the top 81.1%.
Is NovoCure's Return-on-Tangible-Equity too high?
NovoCure's current Return-on-Tangible-Equity is -82.97%. Based on the distribution chart, NovoCure ranks #616 out of 760 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, NovoCure has a GF Score™ of 46/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NovoCure's Return-on-Tangible-Equity compare to NEOG and ESTA?
According to the Medical Devices & Instruments industry distribution chart, NovoCure ranks #616 out of 760 companies for Return-on-Tangible-Equity. This places NovoCure in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.12, based on 760 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on NovoCure and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NovoCure's current Return-on-Tangible-Equity is -82.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovoCure stock overvalued right now?
Based on GuruFocus' analysis, NovoCure (BSP:N2VC34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$8.98, compared to a current price of R$7.08 — trading 21.2% below its estimated fair value. The current Return-on-Tangible-Equity is -82.97%. NovoCure's overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For NovoCure (BSP:N2VC34), the current Return-on-Tangible-Equity is -82.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NovoCure (BSP:N2VC34) Overvalued in 2026?
Based on GuruFocus' analysis, NovoCure stock appears to be undervalued.
The current stock price of R$7.08 is trading 21.2% below its estimated GF Value™ of R$8.98.
GuruFocus considers NovoCure to be Modestly Undervalued.
Key valuation signals for BSP:N2VC34:
Return-on-Tangible-Equity: -82.97%
GF Value™: R$8.98 vs. price of R$7.08 (21.2% below fair value)
No single metric tells the full story. See the BSP:N2VC34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
46GF Score
Get the complete analysis for BSP:N2VC34
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:N2VC34 has been successfully added to your 
